FCGR3A and neoplasm: In addition, antibody-based therapies against tumor-specific antigens can induce antibody-dependent cellular cytotoxicity (ADCC) by NK cells, since low affinity Fc receptor CD16 (FcγRIIIA) is a major activating receptor on NK cells.